# Entact Bio

> Entact Bio is a preclinical-stage biotechnology company in Watertown, Massachusetts developing Enhancement-Targeting Chimeric (ENTAC) molecules — small molecules that recruit deubiquitinases (DUBs) to remove ubiquitin chains from beneficial proteins in order to extend their half-life, relocate them, or restore their function. It is the inverse of targeted protein degradation. Entact Bio publishes **no API, SDK, developer portal, or machine-readable specification**. This file is generated by API Evangelist from public sources; it is not published by Entact Bio.

<!--
generated: '2026-08-12'
method: generated
source: apis.yml + public search results (https://entactbio.com/llms.txt could not be read — the origin answers every path with an HTTP 202 SiteGround captcha challenge)
-->

## APIs

- No public API surface was found. Every path probed on `entactbio.com` — `/openapi.json`, `/swagger.json`, `/api-docs`, `/docs`, `/llms.txt`, `/graphql`, `/api`, and every `/.well-known/*` path including `/.well-known/agent-card.json` and `/.well-known/agent.json` — returned HTTP 202 with an `sg-captcha: challenge` header and a ~180-byte HTML interstitial rather than a document. The challenge is not evaded, so none of these probes is a readable result.
- DNS carries no developer host: `api.entactbio.com`, `docs.entactbio.com`, `developer.entactbio.com`, `portal.entactbio.com` and `app.entactbio.com` are all NXDOMAIN (checked 2026-08-12). Only the apex and `www` resolve, both to 35.209.165.200.
- The GitHub organization `github.com/EntactBio` exists (created 2023-09-26) but publishes zero public repositories.

## Science

- [Encompass platform](https://entactbio.com/science/): End-to-end platform integrating biological, chemical, and computational tools to identify disease targets amenable to protein enhancement, select an optimal DUB for a given target, and design ENTACs optimized to each target-DUB pair.
- ENTAC molecules: bifunctional small molecules that bring a deubiquitinase to a target protein, opposing the ubiquitin-proteasome pathway rather than exploiting it. Indication areas named publicly are oncology, autoimmune disease, and rare genetic disorders.

## Company

- [Website](https://entactbio.com/)
- [Science](https://entactbio.com/science/)
- [Team](https://entactbio.com/team/)
- [News & Publications](https://entactbio.com/news-publications/)
- [Careers](https://entactbio.com/careers/)
- [Contact](https://entactbio.com/contact-us/)
- [LinkedIn](https://www.linkedin.com/company/entact-bio)
- Founded 2022; launched December 2022 with an $81M Series A co-led by Qiming Venture Partners USA and venBio Partners, with participation from Abingworth, Brandon Capital and others.
- Headquarters: 65 Grove St., Suite 303, Watertown, MA 02472, United States.

## Artifacts

- [Domain security probe](https://raw.githubusercontent.com/api-evangelist/entactbio/refs/heads/main/security/entactbio-domain-security.yml): TLS 1.3, no HSTS, no DNSSEC, no CAA, SPF present (Mimecast + Microsoft 365), DMARC present at `p=quarantine`.
- [Well-known probe](https://raw.githubusercontent.com/api-evangelist/entactbio/refs/heads/main/well-known/entactbio-well-known.yml): records the bot-challenge wall on every `/.well-known/*` path — an absence, not a presence.
- [Packages](https://raw.githubusercontent.com/api-evangelist/entactbio/refs/heads/main/packages/entactbio-packages.yml): zero first-party libraries in npm, PyPI, or the company GitHub org.

## Optional

- [Crunchbase](https://www.crunchbase.com/organization/entact-bio)